{"createdAt":"8/2/2020, 1:17:24 PM","timestamp":1596388644486,"Company ID number":"112","DMX_ISSUER_NAME":"BGI Genomics Co Ltd","DMX_ISSUER_ID":"IID000000002812293","Country of Classification":"CHINA","name":"BGI Genomics Co Ltd ","code":"300676","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"深圳华大基因股份有限公司_汪建","group":"board","name":"汪建","title":"董事长,董事","isMale":true,"age":"66","degree":"硕士","salary":"0.00","stockAmount":"190.8万","description":"汪建,男,1954年出生,中国国籍,无境外居留权。硕士、研究员。现任华大基因董事长,华大控股董事长、总经理。曾任华大研究院院长。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_尹烨","group":"board","name":"尹烨","title":"董事","isMale":true,"age":"41","degree":"硕士","salary":"202.5万","stockAmount":"53.76万","description":"尹烨,男,1979年出生,中国国籍,无境外居留权。工程硕士,现任华大基因董事、总经理,华大科技董事。曾任华大控股首席运营官,华大医学(现已与华大科技合并为华大基因)总经理。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_杜玉涛","group":"board","name":"杜玉涛","title":"董事","isMale":false,"age":"43","degree":"博士","salary":"115.9万","stockAmount":"1.5万","description":"杜玉涛,女,1977年出生,中国国籍,无境外居留权。博士,研究员,现任深圳华大基因股份有限公司副总经理、深圳华大生命科学研究院党委书记。曾任深圳华大基因科技有限公司执行副总裁、深圳华大运动控股有限责任公司首席科学家。","lastUpdated":"2018-11-14"},{"id":"深圳华大基因股份有限公司_孙英俊","group":"board","name":"孙英俊","title":"董事","isMale":true,"age":"49","degree":"硕士","salary":"0.00","stockAmount":"20.14万","description":"孙英俊,男,1971年出生,中国国籍,无境外居留权。硕士,经济师、金融理财师。现任华大基因董事,华大控股首席财务官。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_王洪涛","group":"board","name":"王洪涛","title":"董事","isMale":true,"age":"46","degree":"硕士","salary":"0.00","stockAmount":"-","description":"王洪涛先生,投资管理部债券研究负责人、公司投资管理委员会委员、中信现金优势货币市场基金经理.生于1974年,武汉大学物理系理学学士,武汉大学管理学院经济学硕士,曾任平安证券债券部投资经理、平安保险投资管理中心投资组合经理助理、招商证券研发中心产品开发部经理及研发中心总经理助理、光大控股创业投资(深圳)有限公司资产管理部总经理.王先生在投资管理、投资研究方面经验丰富,特别是债券研究与投资方面有突出特长.在平安和光大工作期间,所负责的投资业务取得优良的业绩.","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_陈鹏辉","group":"board","name":"陈鹏辉","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"0.00","stockAmount":"-","description":"陈鹏辉,男,1972年出生,美国国籍。硕士。现任华大基因董事,博远资本创始合伙人。曾任美国圣地亚哥生物技术公司LigandPharmaceuticals研究员,中信资本控股有限公司投资副总裁,尚华医药集团首席运营官、首席财务官、总裁,中国光大控股有限公司医疗基金负责人、董事总经理,红杉资本中国基金合伙人。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_徐爱民","group":"board","name":"徐爱民","title":"独立董事","isMale":true,"age":"53","degree":"博士","salary":"12.48万","stockAmount":"-","description":"徐爱民,男,1967年出生,中国国籍,有境外居留权。博士,教授。现任华大基因独立董事,中山大学达安基因股份有限公司独立董事,中国香港大学内科学系、药理及药剂学系终身教授。同时兼任中国香港大学生物医药技术国家重点实验室主任,中国香港大学抗体及免疫检测服务中心主任。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_吴育辉","group":"board","name":"吴育辉","title":"独立董事","isMale":true,"age":"42","degree":"博士","salary":"12.48万","stockAmount":"-","description":"吴育辉,男,汉族,现年42岁,厦门大学管理学院教授、博士生导师,中国注册会计师。曾任合力泰科技股份有限公司、福耀玻璃工业集团股份有限公司等多家上市公司独立董事。目前兼任上市公司深圳华大基因股份有限公司、深圳顺络电子股份有限公司独立董事。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_蒋昌建","group":"board","name":"蒋昌建","title":"独立董事","isMale":true,"age":"55","degree":"博士","salary":"12.48万","stockAmount":"-","description":"蒋昌建,男,1965年出生,中国国籍,无境外居留权。博士,副教授。现任华大基因独立董事,复旦大学国际关系与公共事务学院副教授,苏州易德龙科技股份有限公司独立董事,三湘印象股份有限公司独立董事。曾任安徽师范大学附属中学教师。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_李松岗","group":"supervisoryCommittee","name":"李松岗","title":"监事会主席","isMale":true,"age":"73","degree":"硕士","salary":"8.630万","stockAmount":"5500","description":"李松岗,男,1947年出生,中国国籍,无境外居留权。硕士。现任华大基因监事。曾任北京大学生命科学学院讲师、副教授、教授。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_李雯琪","group":"supervisoryCommittee","name":"李雯琪","title":"监事","isMale":false,"age":"34","degree":"硕士","salary":"46.39万","stockAmount":"3000","description":"李雯琪,女,1986年出生,中国国籍,无境外居留权。硕士学历。现任华大基因监事、华大基因总经理助理。曾任华大科技日本片区业务经理、实验平台行政总监。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_胡宇洁","group":"supervisoryCommittee","name":"胡宇洁","title":"职工监事","isMale":false,"age":"36","degree":"硕士","salary":"47.40万","stockAmount":"3500","description":"胡宇洁,女,1984年出生,中国国籍,无境外居留权。硕士学历。现任华大基因监事。曾任华大科技人力资源总监。","lastUpdated":"2018-06-02"},{"id":"深圳华大基因股份有限公司_尹烨","group":"manager","name":"尹烨","title":"总经理","isMale":true,"age":"41","degree":"硕士","salary":"202.5万","stockAmount":"53.76万","description":"尹烨,男,1979年出生,中国国籍,无境外居留权。工程硕士,现任华大基因董事、总经理,华大科技董事。曾任华大控股首席运营官,华大医学(现已与华大科技合并为华大基因)总经理。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_徐茜","group":"manager","name":"徐茜","title":"董事会秘书,法务总监","isMale":false,"age":"36","degree":"硕士","salary":"75.18万","stockAmount":"8000","description":"徐茜,女,1984年出生,中国国籍,无境外居留权。硕士,具有深圳证券交易所董事会秘书资格和法律职业资格。现任华大基因董事会秘书、法务总监。曾任深圳华大基因科技服务有限公司法务总监。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_杜玉涛","group":"manager","name":"杜玉涛","title":"副总经理","isMale":false,"age":"43","degree":"博士","salary":"115.9万","stockAmount":"1.5万","description":"杜玉涛,女,1977年出生,中国国籍,无境外居留权。博士,研究员,现任深圳华大基因股份有限公司副总经理、深圳华大生命科学研究院党委书记。曾任深圳华大基因科技有限公司执行副总裁、深圳华大运动控股有限责任公司首席科学家。","lastUpdated":"2018-11-14"},{"id":"深圳华大基因股份有限公司_刘娜","group":"manager","name":"刘娜","title":"副总经理","isMale":false,"age":"41","degree":"博士","salary":"96.37万","stockAmount":"1.29万","description":"刘娜,女,1979年出生,中国国籍,无境外居留权。博士。现任华大基因副总经理。曾任深圳华大基因科技有限公司科技合作事业部RNA业务线总监、制药与生物技术研究业务线总监,深圳华大基因科技服务有限公司董事长、副总裁。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_陈轶青","group":"manager","name":"陈轶青","title":"财务总监","isMale":true,"age":"36","degree":"硕士","salary":"84.17万","stockAmount":"1.41万","description":"陈轶青,男,1984年出生,中国国籍,无境外居留权。硕士,中国注册会计师资格。现任华大基因财务总监。曾任深圳华大基因科技服务有限公司财务总监,东方花旗证券有限公司投资银行部业务总监,东方证券有限公司投资银行部业务副总监,安永华明会计师事务所审计师。","lastUpdated":"2018-06-19"},{"id":"深圳华大基因股份有限公司_王威","group":"manager","name":"王威","title":"首席医学官","isMale":false,"age":"47","degree":"博士","salary":"48.72万","stockAmount":"-","description":"王威,女,1973年出生,中国国籍,无境外居留权。博士,副研究员。现任华大基因首席医学官。曾任华大医学总经理,北京基因研究基因分型平台负责人。","lastUpdated":"2017-06-27"},{"id":"深圳华大基因股份有限公司_李治平","group":"manager","name":"李治平","title":"人力资源总监","isMale":true,"age":"41","degree":"本科","salary":"70.90万","stockAmount":"8300","description":"李治平,男,1979年出生,中国国籍,无境外居留权。本科学历。现任华大基因人力资源总监。曾任深圳华大基因科技有限公司人力资源副总监,深圳华大基因医学有限公司人力资源总监。","lastUpdated":"2018-06-19"}],"companyName":"深圳华大基因股份有限公司","province":"广东省","englishName":"BGI Genomics Co Ltd","industry":"医药生物 — 医疗器械Ⅱ","website":"www.bgi.com","mainBusiness":"通过基因检测等手段，为医疗机构、科研机构、企事业单位等提供基因组学类的诊断和研究服务","productsName":["生育健康基础研究和临床应用服务","肿瘤防控及转化医学类服务","多组学大数据服务与合成业务","感染防控基础研究和临床应用服务","精准医学检测综合解决方案"],"actualController":"汪建","actualControllerSharePercentage":"32.99%","registeredCapital":"4亿元","employeeAmount":"3585","phone":"86-0755-36307065","location":"广东省深圳市盐田区洪安三街21号华大综合园7栋7层-14层","chineseDescription":"深圳华大基因股份有限公司的主营业务为通过基因检测等手段，为医疗机构、科研机构、企事业单位等提供基因组学类的诊断和研究服务。公司坚持规范治理与运作，恪守高质量发展的理念，积极与投资者沟通，努力践行并承担社会责任，在行业、资本市场及社会公益扶贫等领域荣获多个奖项。报告期内，公司获得 “首届质量创新大赛优秀奖”、“高质量发展先锋”、深圳市市长质量奖经济类铜奖，子公司天津华大医学检验所有限公司获得了第六届滨海新区质量奖，该奖项是对公司推进高质量发展工作的认可；此外，公司还获得了“2019年度中国最受尊敬企业”、“价值合作伙伴奖”、“金牛奖.2018年度投资者关系管理奖”、“中国证券金紫荆奖.最佳IR团...查看全部▼深圳华大基因股份有限公司的主营业务为通过基因检测等手段，为医疗机构、科研机构、企事业单位等提供基因组学类的诊断和研究服务。公司坚持规范治理与运作，恪守高质量发展的理念，积极与投资者沟通，努力践行并承担社会责任，在行业、资本市场及社会公益扶贫等领域荣获多个奖项。报告期内，公司获得 “首届质量创新大赛优秀奖”、“高质量发展先锋”、深圳市市长质量奖经济类铜奖，子公司天津华大医学检验所有限公司获得了第六届滨海新区质量奖，该奖项是对公司推进高质量发展工作的认可；此外，公司还获得了“2019年度中国最受尊敬企业”、“价值合作伙伴奖”、“金牛奖.2018年度投资者关系管理奖”、“中国证券金紫荆奖.最佳IR团队”、“首届A股科技龙头50嘉年华.最佳投资者服务奖”、“全球企业社会责任健康促进奖”、“中国扶贫开发协会脱贫攻坚优秀会员单位”、“2018年度优秀公益项目奖”（宫颈癌防控专项）等多项荣誉，有效提升了公司的影响力和美誉度。收起▲","foundedDate":"2010-07-09","goPublicDate":"2017-07-14","companyHistory":"（一）有限公司成立情况。\n　　公司前身华大医学成立于2010年7月9日，由华大控股、华大农业共同出资设立。华大医学成立时注册资本1,000万元，其中华大控股以货币出资950万元，占公司注册资本的95%，华大农业以货币出资50万元，占公司注册资本的5%。首期出资由华大控股出资190万元，华大农业出资10万元，剩余出资于华大医学设立后两年内缴足。\n　　2010年7月7日，深圳永信瑞和会计师事务所出具《验资报告》（深永信会验字［2010］198号），验证截至2010年7月6日，华大医学已收到股东缴纳的注册资本第一期合计200万元，其中华大农业以货币方式实缴出资10万元，华大控股以货币方式实缴出资190万元。\n　　2010年7月9日，深圳市市场监督管理局向公司核发了《企业法人营业执照》，注册号为4403011004800923。\n　　2012年9月25日，华大医学股东会会议作出决议，申请延长出资期限二年。\n　　2012年10月24日，深圳市市场监督管理局核准公司出资期限由2012年7月9日延至2014年7月9日。\n　　2013年3月11日，深圳中瑞泰会计师事务所（普通合伙）出具《验资报告》（深中瑞泰验字[2013]第007号），验证截至2013年3月10日，华大医学已收到股东缴纳的注册资本第二期合计800万元，华大控股以货币出资760万元，华大农业以货币出资40万元。连同第一期出资200万元，公司累计实收资本1,000万元。其中，华大农业以货币方式实缴出资50万元，华大控股以货币方式实缴出资950万元，实缴出资占已登记注册资本额的100%。\n　　2013年3月18日，深圳市市场监督管理局对公司本次变更进行了备案。\n　　（二）股份公司设立情况。\n　　公司是由华大医学整体变更设立的股份有限公司。\n　　2015年6月15日，安永华明出具了《专项审计报告》（安永华明（2015）专字第61049184_H02号），审验确认截至2015年5月31日，华大医学的净资产为2,627,064,895.20元。\n　　2015年6月19日，深圳德正信国际资产评估有限公司出具了《深圳华大基因医学有限公司股份制改制项目评估报告》（德正信综评报字[2015]第037号），确认截至2015年5月31日，华大医学的净资产评估值为275,377.84万元。\n　　2015年6月22日，华大医学股东会会议作出决议，同意将华大医学截至2015年5月31日，经安永华明审计的账面净资产2,627,064,895.20元中的326,119,339元折为深圳华大基因股份有限公司普通股326,119,339股（每股人民币1元），余额2,300,945,556.20元计入资本公积。华大医学全体股东作为发起人，以各自在华大医学中的股权所对应的净资产认购股份有限公司的股份。同日，华大医学全体股东签订《关于深圳华大基因医学有限公司整体变更为深圳华大基因股份有限公司之发起人协议》，就发起人的各项权利和义务、股份公司的设立方式、名称、住所、经营范围、注册资本及股本比例、出资方式等相关事宜进行了约定。\n　　2015年6月22日，公司召开了关于股份有限公司设立的股东大会，全体发起人一致决定按华大医学经安永华明审计的账面净资产值折股，将华大医学整体变更为股份有限公司，该次会议还审议通过了新的公司章程及其他事项，并选举产生了第一届董事会董事和第一届监事会的股东代表监事。\n　　2015年6月23日，安永华明出具了《验资报告》（安永华明（2015）验字第61049184_H01号），审验确认截至2015年6月23日止，全体发起人以其拥有的华大医学截至2015年5月31日止之净资产计人民币2,627,064,895.20元折股为326,119,339.00股，每股面值人民币1元，缴纳注册资本计人民币326,119,339.00元，余额计入资本公积。\n　　2015年6月23日，深圳市市场监督管理局向公司核发了《企业法人营业执照》，注册号为440301104800923，注册资本为326,119,339元。\n　　根据公司在2015年8月8日召开股东大会审议通过的《关于公司首次公开发行人民币普通股（A股）并在创业板上市方案的议案》和在2017年3月17日召开2016年年度股东大会通过的《关于修改公司首次公开发行人民币普通股（A股）股票并在创业板上市的议案》以及于2017年6月23日收到中国证券监督管理委员会《关于核准深圳华大基因股份有限公司首次公开发行股票的批复》（证监许可[2017]1023号），截止2017年7月11日，本公司向社会公开发行人民币普通股40,100,000股，面值为每股人民币1.00元，发行后的注册资本为人民币400,100,000元。本次发行新股募集资金总额546,964,000.00元，扣减不含税发行费用人民币63,102,660.38元，实际募集资金净额483,861,339.62元。经深圳证券交易所《关于深圳华大基因股份有限公司人民币普通股股票在创业板上市的通知》（深证上[2017]440号）同意，公司发行的人民币普通股股票于2017年7月14日在深圳证券交易所创业板上市，股票简称“华大基因”，股票代码“300676”。2017年9月28日，本公司完成相关工商变更登记手续，至此，华大控股直接持有本公司37.18%股权。收起▲","shareholders":[],"englishDescription":"BGI Genomics Co., Ltd. is a China-based company principally engaged in the diagnosis and research of genomics. The Company's main products and services include reproductive health basic research and clinical application services, basic science research services (genome sequencing, bioinformatics analysis and other multithreaded solutions), complex disease basic research and clinical application services, as well as drugs basic research and clinical application services. The Company mainly provides services for domestic and overseas academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals and medical institutions, among others.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"206.43","Price to sales (ttm)":"21.83","Price to book (mrq)":"14.71","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"9.57","Lt debt to equity (mrq)":"2.85","Return on investment (ttm)":"6.61","Return on equity (ttm)":"5.10","Income statement":{"Revenue":"2,800.41","Total revenue":"2,800.41","Cost of revenue, total":"1,302.64","Gross profit":"1,497.77","Selling/general/admin. expenses, total":"901.51","Research & development":"259.17","Depreciation/amortization":"81.48","Interest exp.(inc.),net-operating, total":"(27.76)","Unusual expense (income)":"(1.49)","Other operating expenses, total":"(44.06)","Total operating expense":"2,471.48","Operating income":"328.93","Other, net":"(0.75)","Net income before taxes":"328.19","Provision for income taxes":"49.67","Net income after taxes":"278.52","Minority interest":"(2.19)","Net income before extra. items":"276.33","Net income":"276.33","Income available to com excl extraord":"276.33","Income available to com incl extraord":"276.33","Diluted net income":"276.33","Diluted weighted average shares":"400.10","Diluted eps excluding extraord items":"0.69","Dps - common stock primary issue":"0.10","Diluted normalized eps":"0.69","Gain (loss) on sale of assets":"(2.44)"},"Balance sheet":{"Cash":"0.07","Cash & equivalents":"725.41","Short term investments":"482.22","Cash and short term investments":"1,207.70","Accounts receivable - trade, net":"1,232.43","Total receivables, net":"1,393.88","Total inventory":"342.97","Prepaid expenses":"249.11","Other current assets, total":"9.84","Total current assets":"3,203.51","Property/plant/equipment, total - gross":"2,027.43","Accumulated depreciation, total":"(613.33)","Property/plant/equipment, total - net":"1,414.10","Goodwill, net":"47.11","Intangibles, net":"177.81","Long term investments":"613.09","Note receivable - long term":"23.84","Other long term assets, total":"429.67","Total assets":"5,909.12","Accounts payable":"171.16","Accrued expenses":"123.62","Notes payable/short term debt":"50.00","Other current liabilities, total":"789.72","Total current liabilities":"1,134.50","Long term debt":"0.00","Capital lease obligations":"65.83","Total long term debt":"65.83","Total debt":"115.83","Deferred income tax":"26.17","Minority interest":"86.99","Other liabilities, total":"281.58","Total liabilities":"1,595.07","Common stock, total":"400.10","Additional paid-in capital":"2,807.65","Retained earnings (accumulated deficit)":"1,056.32","Other equity, total":"49.98","Total equity":"4,314.05","Total liabilities & shareholders' equity":"5,909.12","Total common shares outstanding":"400.10","Tangible book value per share, common eq":"10.22"},"Cash flow":{"Cash receipts":"2,782.74","Cash payments":"(1,218.25)","Cash taxes paid":"(97.06)","Changes in working capital":"(1,243.17)","Cash from operating activities":"224.25","Capital expenditures":"(626.44)","Other investing cash flow items, total":"(216.23)","Cash from investing activities":"(842.67)","Financing cash flow items":"388.02","Total cash dividends paid":"(40.01)","Cash from financing activities":"348.01","Foreign exchange effects":"5.21","Net change in cash":"(265.19)","Issuance (retirement) of debt, net":"(8.00)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"164.15","52 Week High":"199.40","52 Week Low":"55.69","Pricing date":"","10 Day Average Trading Volume":"10.60","Market Capitalization":"65,676.41","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"209.39","Beta":"--","1 Day Price Change":"-0.82","13 Week Price Return (Daily)":"55.98","26 Week Price Return (Daily)":"106.48","5 Day Price Return (Daily)":"8.59","52 Week Price Return (Daily)":"161.05","Year To Date Price Return (Daily)":"138.94","Month to Date Price Return (Daily)":"5.29","Price Relative to S&P500 (4 Week)":"-8.98","Price Relative to S&P500 (13 Week)":"22.63","Price Relative to S&P500 (26 Week)":"61.72","Price Relative to S&P500 (52 Week)":"77.41","Price Relative to S&P500 (YTD)":"82.75"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.69","EPS excl. Extra Items (TTM)":"0.80","EPS Normalized (Annual)":"0.69","Revenue per Share (Annual)":"7.00","Revenue per Share (TTM)":"7.52","Book Value (Per Share Annual)":"10.78","Book Value (Per Share Quarterly)":"11.16","Tangible Book Value (Per Share Annual)":"10.22","Tangible Book Value (Per Share Quarterly)":"10.60","Cash Per Share (Per Share Annual)":"3.02","Cash Per Share (Per Share Quarterly)":"5.02","Cash Flow (Per Share Annual)":"1.30","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.10","Dividends (Per Share TTM)":"0.10","EBITD (Per Share TTM)":"0.87","EPS Basic excl. Extra Items (Annual)":"0.69","EPS Basic excl. Extra Items (TTM)":"0.80","EPS incl. Extra Items (Annual)":"0.69","EPS incl. Extra Items (TTM)":"0.80","Free Cash Flow (Per Share TTM)":"0.20","Dividend (Per Share 5Y)":"0.14"},"Valuation":{"P/E excl. Extra Items (Annual)":"237.67","P/E excl. Extra Items (TTM)":"206.43","P/E Normalized (Annual)":"238.76","Price to sales (Annual)":"23.45","Price to sales (TTM)":"21.83","Price to Tangible Book (Annual)":"16.06","Price to Tangible Book (Quarterly)":"15.49","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"810.29","Price to Book (Annual)":"15.22","Price to Book (Quarterly)":"14.71","P/E Basic excl. Extra Items (TTM)":"106.51","P/E excl. Extra Items High (TTM)":"--","P/E excl. Extra Items Low (TTM)":"--","P/E incl. Extra Items (TTM)":"206.43","Net Debt (Interim)":"-1,581.26","Net Debt (Annual)":"-1,091.87","Dividend Yield (5Y)":"--","Dividend Yield":"0.06","Current Dividend Yield (TTM)":"0.06"},"Financial Strength":{"Free Cash Flow (Annual)":"-442.19","Current Ratio (Annual)":"2.82","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"1.53","Payout Ratio (Annual)":"14.48","Quick Ratio (Annual)":"2.52","Total Debt/Total Equity (Annual)":"2.68","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"2.48","Long Term Debt/Equity (Quarterly)":"2.85","Quick Ratio (Quarterly)":"2.13","Total Debt/Total Equity (Quarterly)":"9.57","Free Cash Flow (TTM)":"81.05","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"12.58"},"Margins":{"Gross Margin (Annual)":"53.48","Gross Margin (TTM)":"53.02","Net Profit Margin % (Annual)":"9.95","Net Profit Margin (TTM)":"10.51","Operating Margin (Annual)":"11.75","Operating Margin (TTM)":"12.72","Pretax Margin (TTM)":"12.47","Pretax Margin (Annual)":"11.72","Operating Margin (5Y)":"19.06","Pretax Margin (5Y)":"19.43","Free Operating Cash Flow/Revenue (5Y)":"-13.49","Free Operating Cash Flow/Revenue (TTM)":"2.69","Gross Margin (5Y)":"55.66","Net Profit Margin (5Y)":"16.56"},"Management Effectiveness":{"Return on Assets (Annual)":"4.99","Return on Equity (TTM)":"5.10","Return on Average Equity (Annual)":"6.52","Return on Average equity (TTM)":"7.30","Return on Investment (Annual)":"6.25","Return on Investment (TTM)":"6.61","Return on Average Assets (5Y)":"7.70","Return on Average Equity (5Y)":"9.45","Return on Investment (5Y)":"9.66","Asset Turnover (Annual)":"0.50","Asset Turnover (TTM)":"0.48","Inventory Turnover (Annual)":"4.45","Inventory Turnover (TTM)":"3.30","Net Income/Employee (Annual)":"82,707.97","Net Income/Employee (TTM)":"88,214.01","Receivables Turnover (Annual)":"2.26","Receivables Turnover (TTM)":"2.23","Revenue/Employee (Annual)":"831,599.70","Revenue/Employee (TTM)":"839,301.30"},"Growth":{"Revenue Growth (Quarterly YoY)":"35.78","Revenue Growth Rate (5Y)":"19.86","EPS Growth (Quarterly YoY)":"42.59","EPS Growth (TTM YoY)":"-17.17","EPS Growth Rate (5Y)":"43.13","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"15.60","Revenue Growth (Per Share 5Y)":"8.62","Revenue Growth Rate (3Y)":"17.84","EPS Growth Rate (3Y)":"-9.25","Book Value Growth Rate (Per Share 5Y)":"-4.83","Tangible Book Value Total Equity CAGR (5Y)":"33.00","Capital Spending growth rate 5 year":"2.41","EBITDA CAGR (5Y)":"30.06","EBITDA Interim CAGR (5Y)":"--","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"65.83","Net Profit Margin Growth Rate (5Y)":"13.98"},"Income Statement":{"Revenue (Annual)":"2,800.41","Revenue (TTM)":"3,008.90","EBITD (Annual)":"540.75","EBITD (TTM)":"349.50","Earnings Before Taxes (Annual)":"328.19","Earnings Before Taxes (TTM)":"375.25","Net Income to Common (Annual)":"276.33","Net Income to Common (TTM)":"318.16","Earnings Before Taxes Normalized (Annual)":"326.69","Net Income Available to Common Normalized (Annual)":"275.07","Diluted Normalized EPS excl. Extra Items (TTM)":"0.79"}}}